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cant (p < 0.05) probability of goal attainment. Results related
to titration were equivocal. When compared to 1st and 2nd
tier statins (lovastatin, pravastatin, simvastatin, ezetimibe/
simvastatin), 3rd tier statins (n = 1171) demonstrated results
similar to atorvastatin. Condition indices were consistently <30.
Prescription data period: October 2004 to July 2006. CONCLU-
SION: Atorvastatin and 3rd tier statins were signiﬁcantly better
at achieving treatment goal in high-risk, hyperlipidemic patients.
Otherwise, atorvastatin and 3rd tier statins failed to outperform
comparators.
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OBJECTIVES: To empirically evaluate the predictive perfor-
mance and risk factor identiﬁcation of P-Course and compare it
to logistic regression (LR) using patients screened for the pres-
ence of coronary heart disease (CHD). P-Course is a web-based
naive Bayes classiﬁcation (NBC) tool which special feature is its
ability to utilize informative priors in model construction.
METHODS: 597 CHD-suspected patients underwent coronary
angiography. P-Course was compared to various forms of novel
LR approaches (full LR, backward stepwise selection using
Bayesian Information Criterion (BIC), and Bayesian Model
Averaging (BMA) with medically supported interactions). Pre-
dictive performance was measured as the proportion of cor-
rectly classiﬁed patients. The dataset was randomly split into
training and test sets. Performance was measured separately for
four different sizes of training sets (150, 200, 300, and 450).
For each size, the experiment was replicated 20 times to
improve accuracy. RESULTS: P-Course outperformed LR
approaches: the respective ranges for the average accuracies of
P-Course, full LR, stepwise BIC, and BMA with same datasets
were 0.78–0.81, 0.70–0.81, 0.70–0.80, and 0.78–0.80. In total
splits modeled (N = 3000–9000), P-Course predicted correctly
on average 63 cases more than the best comparator, BMA. The
analyses further illustrate that relevant prior information
improves P-Course’s accuracy, in particular when the training
dataset is relatively small: average accuracies with informative
and uninformative priors using training sets of sizes 25–50
were 0.70–0.71 and 0.66–0.68, respectively. In variable screen-
ing, P-Course yielded medically sensible choices of variables
regarded as the most likely risk factors for CHD. CONCLU-
SION: In addition to previous work done with P-Course (e.g.,
Naïve Bayesian Fusion and decision rationality analysis), this
analysis demonstrated the tool’s additional value in comparison
to the LR approaches. When the estimation of e.g. propensity
scores or adverse events is of concern, NBC can offer additional
predictive value compared to LR. In medicine, even one unnec-
essary faulty prediction is too much.
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OBJECTIVES: Due to joint risk factors, positive screening results
are often not only associated with mortality speciﬁc for the target
disease of screening, but also with an increased mortality due to
other causes. Most decision-analytic models do not consider this
association leading to potentially biased results. Our goal was to
develop a tool which helps to adjust for such joint mortality.
METHODS: We developed a function HR_other(HR_target)
characterizing the relationship between two mortality hazard
ratios (HRs). HR_target compares the mortality rate due to the
target disease among those at high risk versus low risk. HR_other
compares the respective mortality rates not directly related to
the target disease. We postulated several properties that must be
fulﬁlled by this function: 1) if the screening test result does not
explain the mortality (i.e. HR_other(HR_target) = 1) of the
target disease it also does not explain mortality due to other
causes; 2) the function HR_other(HR_target) is strictly increas-
ing in HR_target; 3) the relationship of HRs below 1 is derived
by taking the reciprocal values of the corresponding HRs above
1; 4) the function has an upper bound; 5) in the range of HRs
above 1, HR_target exceeds HR_other; and 6) the function
HR_other(HR_target) is continuously differentiable. We created
a function sufﬁcing all postulated properties and applied it in the
context of predictive coronary artery disease (CAD) screening.
We ﬁtted the function based of published HRs. Finally, we
applied this function to hypothetic screening methods, for which
only the HRs due to CAD were assumed to be known. The
generated HR_other can be used by decision-analysts for incor-
poration into their CAD decision-analytic models. CONCLU-
SION: We created a useful function that can be used for the
adjustment of differential non-target-disease related mortality
among risk groups in decision-analytic screening models. This
should result in more valid modeling results.
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OBJECTIVES: A comparative cost-effectiveness analysis of
generic versions of atorvastatin (atva) and simvastatin (simva)
with rosuvastatin (rosva) in patients with primary hypercholes-
terolemia in the RF. METHODS: This study compared two
brands of atva—Atoris (KRKA) and Tulip (LEK), and one of
simva—Vasilip (KRKA) with rosva—Crestor (AZ). Efﬁcacy data
in terms of percentage reduction in LDL cholesterol and propor-
tion of patients to European LDL cholesterol goals was taken
from the STELLAR trial. Price per pack data was obtained
in RUR from the wholesale Protek price-list (20.07.2006).
Exchange rate is 25.98 RUR per 1 USD and 34.75 RUR per 1
Euro. Meta-analysis of all available comparative clinical trials
has shown a relative effective dose of 1:3 for rosva compared
with atva and 1:8 for rosva vs simva. Hence cost and
efﬁcacy data for rosva 10 mg is compared with atva 30 mg
(20 mg + 10 mg) and with simva 80 mg (40 mg + 40 mg) in the
form cost per patient per year and cost per patient to European
LDL cholesterol goals. RESULTS: The cost per patient to LDL-C
goal for Crestor 10 mg is 17,914 RUR, for Atoris 30 mg, Tulip
30 mg and Vasilip 80 mg is 25,968; 25,372 and 27,692 RUR
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